This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Tosatoxumab
DrugBank Accession Number
DB16557
Background

Tosatoxumab is a fully-human monoclonal antibody (IgG1λ) targeting the Staphylococcus aureus alpha-toxin or the S. aureus alpha-hemolysin1,2,3 and thereby preserving human immune cells by protecting against destruction of host cells mediated by the toxin.3

Type
Biotech
Groups
Investigational
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Protein Chemical Formula
Not Available
Protein Average Weight
Not Available
Sequences
Not Available
Synonyms
  • Tosatoxumab
External IDs
  • AR-301
  • AR301
  • KBSA-301
  • KBSA301

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action

Staphylococcus aureus alpha-toxin is a virulence factor secreted by methicillin-resistant S. aureus (MRSA) and methicillin-sensitive S. aureus (MSSA), with S. aureus being a leading cause of hospital-acquired lower respiratory tract infections and bloodstream, skin, soft tissue, and surgical site infections.3 Tosatoxumab acts as a monoclonal antibody against infections caused by MRSA and MSSA3 by targeting the S. aureus alpha-toxin1,2,3, with its mode of action being independent of the antibiotic resistance profile of S. aureus.3

Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
International/Other Brands
Salvecin (Aridis Pharmaceuticals)

Categories

Drug Categories
Not Available
Chemical TaxonomyProvided by Classyfire
Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
6AA3OC17QR
CAS number
1374419-41-6

References

General References
  1. Kaplon H, Muralidharan M, Schneider Z, Reichert JM: Antibodies to watch in 2020. MAbs. 2020 Jan-Dec;12(1):1703531. doi: 10.1080/19420862.2019.1703531. [Article]
  2. PubMed Central (PMC): Passive Monoclonal and Polyclonal Antibody Therapies [Link]
  3. Aridis Pharmaceuticals: AR-301: Fully Human mAb Against Staphylococcus aureus [Link]
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3RecruitingTreatmentBacterial Infections / Pulmonary Infections / Staphylococcus Aureus / Ventilator Associated Bacterial Pneumonia1
1, 2CompletedTreatmentPneumonia Due to Staphylococcus Aureus1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created at February 08, 2021 16:10 / Updated at February 21, 2021 18:55